Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Current Leases (2021 - 2025)

Senti Biosciences has reported Current Leases over the past 5 years, most recently at $5.3 million for Q4 2025.

  • For Q4 2025, Current Leases rose 14.7% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $5.3 million, up 14.7%, while the annual FY2025 figure was $5.3 million, 14.7% up from the prior year.
  • Current Leases for Q4 2025 was $5.3 million at Senti Biosciences, up from $5.2 million in the prior quarter.
  • Over five years, Current Leases peaked at $5.3 million in Q4 2025 and troughed at $96000.0 in Q3 2023.
  • A 5-year average of $3.2 million and a median of $4.0 million in 2023 define the central range for Current Leases.
  • Biggest five-year swings in Current Leases: tumbled 95.14% in 2024 and later surged 4711.0% in 2025.
  • Year by year, Current Leases stood at $1.7 million in 2021, then rose by 10.27% to $1.9 million in 2022, then surged by 109.73% to $4.0 million in 2023, then increased by 15.28% to $4.6 million in 2024, then increased by 14.7% to $5.3 million in 2025.
  • Business Quant data shows Current Leases for SNTI at $5.3 million in Q4 2025, $5.2 million in Q3 2025, and $5.0 million in Q2 2025.